Feb 17–20, 2025 | Keystone Resort, Keystone, CO, United States
Scientific Organizers:
Jean-Philippe Julien and Katherine Harris

-
Scientific Organizers: Jean-Philippe Julien and Katherine Harris
Jean-Philippe Julien
Katherine Harris
***Meeting program subject to change.
Available Formats: = In Person = On DemandMonday, February 17, 2025
Fundraising
Booking Function
Merchandise Options
Registration Options
Tuesday, February 18, 2025
Session Chair
Session Chair
Monoclonal Antibodies & TCRs: Shaping the Future of Therapeutic Design
Remote Presentation: Trim-Away: TRIM21-based Modalities for Intracellular Targeted Protein Degradation
Short Talk: Polymeric Lysosomal-Targeting Chimeras: Extracellular Targeted Protein Degradation Without Co-opting Lysosome-Targeting Receptors
Novel Approaches for Extracellular Targeted Protein Degradation (eTPD)
Fc-engineering to Increase the Therapeutic Index for Antibody Fragment-based Radioimmunotherapy
S-4321, A Novel Dual-cell Bidirectional PD-1:FcγRIIb Selective Agonist Antibody for the Treatment of Autoimmune Disease
Targeting MUC16 in Pancreatic Cancer: Structural and Functional Analysis of the Humanized AR9.6 Antibody
Targeting PD-L1 Blockade to Dendritic Cells through Simultaneous Binding to CD11c Enhances Antitumor Efficacy
Development of an Influenza Neutralizing Antibody Cocktail using DNA-based Delivery
Trans-splicing Mediated Recombination to Generate Multi-specific Antibodies
Structure-guided Disulfide Engineering Restricts Antibody Conformation to Elicit TNFR Agonism in Anti-cancer Therapeutics
Therapeutic Area Leader Dementias, Expert Scientist and Medical Director
Principal Scientist
Associate Professor
Group Leader & Professor
Discovery of XB010, a Next Generation 5T4-targeting ADC
Proximity-based Bispecific Antibody Strategies to Address Disease
Wednesday, February 19, 2025
Novel Approaches for Conditionally-Active and Brain-Permeable Antibodies
Developing Immunostimulating Antibodies to Deliver Agonism Without Toxicity
TCR Biologics
Identifying & Building Around Optimal Targets for Oncology Therapies
Short Talk: Evaluating Peripheral Delivery of Anti-PrP Antibody AZ59 for Brain PrP Targeting and Therapeutic Potential in Prion Disease
Short Talk: A Monoclonal Antibody that Neutralizes both Long- and Short-chain Three Finger Snake Venom Neurotoxins
A Yeast Manufacturing Platform for VHH-Fc Type Molecules
Genetically Engineered B Cell Medicines for Sustained in Vivo Delivery of Therapeutic Biologics
Antibody Therapeutics Against Respiratory RNA Viruses
Antibody-based Strategies to Block the Transmission of Malaria
Thursday, February 20, 2025
Targeting FcRn for the Generation of Therapeutics for Antibody-Mediated Disease
Optimization and Application of Fc-Containing Bispecific Antibodies
Engineering of Antibodies for Optimal FcRn Engagement
Short Talk: How Format Impacts Activity: Structure-activity Relationship for Optimal FcRn Engagement of Fc-based Therapeutics
Short Talk: Structure-PK Relationship: Complex Antibody Format Affects Pharmacokinetic Properties via FcRn Recycling
Biocheminformatics – Enabling Data Science for Macromolecular Drug Discovery
Integrating High-throughput in vivo Screening with AI-guided Protein Design to Select Brain Shuttles with Optimal Pharmacokinetics, Biodistribution, and Other Drug-like Properties
Rapid AI-Driven Design of Broadly Neutralizing Antibodies Targeting the HIV-1 Envelope Glycoprotein
Harnessing Protein Language Models and Large-Scale Functional Data to Generate Novel, Functionally Active Antibody Therapeutics
One-shot Optimization of Antibody Developability and Affinity by Computational Design
Optimization of Mono- and Multi-Specific Antibodies Using Machine Learning and Atomistic Design
Targeting KRAS Mutation Diversity with Epivolve®: A Novel Approach for Precision Cancer Therapeutics and Diagnostics
Mechanistic Modeling Guides Bispecific Antibody Design and Target Selection for Maximizing Therapeutic Window
Bispecific Immune Synapse Engagers for Cancer Immunotherapy
Bispecific Antibody Combination Strategies for Treating Solid Tumors
Optimizing BBB-Crossing Antibodies and Antibody-Targeted Cargo
Short Talk: Utilizing Cis-binding in T Cell Engagers: Theoretical Modeling to Guide 2+1 and Multi-specific TCE Design
Friday, February 21, 2025
Subscribe for Updates